Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Chae Eun | - |
dc.contributor.author | Yoon, Moon Sup | - |
dc.contributor.author | Jo, Min Jeong | - |
dc.contributor.author | Kim, Seo Yeon | - |
dc.contributor.author | Lee, Jae Min | - |
dc.contributor.author | Kang, Su Jeong | - |
dc.contributor.author | Park, Chun-Woong | - |
dc.contributor.author | Kim, Jin-Seok | - |
dc.contributor.author | Shin, Dae Hwan | - |
dc.date.accessioned | 2023-11-08T06:45:31Z | - |
dc.date.available | 2023-11-08T06:45:31Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/151889 | - |
dc.description.abstract | Ovarian cancer has a high mortality rate due to difficult detection at an early stage. It is necessary to develop a novel anticancer treatment that demonstrates improved efficacy while reducing toxicity. Here, using the freeze-drying method, micelles encapsulating paclitaxel (PTX) and sorafenib (SRF) with various polymers were prepared, and the optimal polymer (mPEG-b-PCL) was selected by measuring drug loading (%), encapsulation efficiency (%), particle size, polydispersity index, and zeta potential. The final formulation was selected based on a molar ratio (PTX:SRF = 1:2.3) with synergistic effects on two ovarian cancer cell lines (SKOV3-red-fluc, HeyA8). In the in vitro release assay, PTX/SRF micelles showed a slower release than PTX and SRF single micelles. In pharmacokinetic evaluation, PTX/SRF micelles showed improved bioavailability compared to PTX/SRF solution. In in vivo toxicity assays, no significant differences were observed in body weight between the micellar formulation and the control group. The anticancer effect of PTX/SRF combination therapy was improved compared to the use of a single drug. In the xenografted BALB/c mouse model, the tumor growth inhibition rate of PTX/SRF micelles was 90.44%. Accordingly, PTX/SRF micelles showed improved anticancer effects compared to single-drug therapy in ovarian cancer (SKOV3-red-fluc). © 2023 by the authors. | - |
dc.format.extent | 20 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/pharmaceutics15041206 | - |
dc.identifier.scopusid | 2-s2.0-85154547949 | - |
dc.identifier.wosid | 000979359500001 | - |
dc.identifier.bibliographicCitation | Pharmaceutics, v.15, no.4, pp 1 - 20 | - |
dc.citation.title | Pharmaceutics | - |
dc.citation.volume | 15 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 20 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | COPOLYMER MICELLES | - |
dc.subject.keywordPlus | DELIVERY-SYSTEMS | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | VINBLASTINE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | STRATEGIES | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordAuthor | antitumor | - |
dc.subject.keywordAuthor | combination therapy | - |
dc.subject.keywordAuthor | micelle | - |
dc.subject.keywordAuthor | mPEG-b-PCL | - |
dc.subject.keywordAuthor | ovarian cancer | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | sorafenib | - |
dc.identifier.url | https://www.mdpi.com/1999-4923/15/4/1206 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.